Basking Biosciences is a clinical-stage biopharmaceutical company developing BB-031, a first-in-class, reversible RNA aptamer that targets von Willebrand Factor (vWF) with rapid onset and short duration of effect. The company reported positive Phase 1 results in 2023 showing safety, tolerability, no serious adverse events, and dose-dependent inhibition of vWF. Basking plans to initiate a Phase 2 proof-of-concept trial (the RAISE trial) in acute ischemic stroke patients in 2024. It is also advancing BB-025, a rapid-acting reversal oligonucleotide, through a Phase 1 clinical program. Basking will use the proceeds from its recent financing to accelerate clinical development of BB-031 and BB-025. The company leverages two decades of translational RNA aptamer research from the lab of Dr. Bruce Sullenger. Basking Biosciences is developing the first reversible thrombolytic therapy for acute ischemic stroke (AIS). Its lead candidate, DTRI-031, is an RNA aptamer that inhibits von Willebrand Factor (vWF); the company is co-developing a matched oligonucleotide reversal agent, DTRI-025, for rapid, as-needed neutralization. The paired therapy aims to extend the treatment window for thrombolysis to 24 hours post stroke onset and expand the population eligible for acute intervention. DTRI-031 has demonstrated potent vessel recanalization in multiple murine and canine preclinical models. The program was expected to enter human clinical trials in Q2 2021. Basking was founded in 2019 and is advancing clinical development after an initial $5.4M Seed financing.

Total raised

$60M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2024